Search or ask a question

How do you overcome estrogen dominance?

Answers from top 5 papers

PDF

Open Access

More filters

Papers (5)	Insight
Open access•Journal Article•DOI Towards optimal hormonal treatment of male to female gender identity disorder Rosemary J Basson 01 Jan 2001 10 Citations	Both theoretical arguments and clinical experience support the use of doses of estrogen that would be physiological for a biological woman but, nevertheless, do allow feminization.
Journal Article•DOI Analysis of the progesterone displacement of its human serum albumin binding site by β-estradiol using biochromatographic approaches: effect of two salt modifiers Claire André, Y Jacquot, Tong Thanh Truong, M. Thomassin, Jean-François Robert, Y. C. Guillaume - Show less +5 more 05 Nov 2003-Journal of Chromatography B 29 Citations	This study showed that it must be useful to carry out more in vivo test on the magnesium supplementation effect for women who suffer from estrogen dominance syndrome.
Journal Article•DOI Apoptotic action of estrogen. R. X.-D. Song, Richard J. Santen - Show less +1 more 01 Jan 2003-Apoptosis 109 Citations	The effects of estrogen are estrogen-receptor dependent.
Journal Article•DOI Variation in the responsiveness of female rats to ovarian hormones as a function of preceding hormonal deprivation. Frank A. Beach, Robert K. Orndoff - Show less +1 more 01 Sep 1974-Hormones and Behavior 55 Citations	The data suggest that the response to estrogen decreases after estrogen deprivation.
Journal Article•DOI Plasma concentrations of unconjugated and conjugated estrogens and gonadotrophins following application of various estrogen preparations after oophorectomy and in the menopause. J. R. Strecker, Ch. Lauritzen, L. Goessens - Show less +2 more 01 Feb 1979-Maturitas 21 Citations	Good tolerance of estrogen therapy with significantly elevated estrogen concentrations in plasma can be obtained transcutaneously in the form of estrogen ointments.

My columns

Related Questions

How can I increase estrogen and testosterone naturally?2 answers

How can I increase my estrogen level during pregnancy?4 answers

How can I increase my testosterone and estrogen?5 answers

How to get rid of estrogen fat?9 answers

How to get rid of estrogen weight gain?6 answers

How to increase estrogen naturally Reddit?8 answers

See what other people are reading

What are the most commonly used tools and methods for evaluating lumbar spine function in research studies?

Various tools and methods are utilized to evaluate lumbar spine function in research studies. Inclinometers are commonly preferred for measuring spinal movements due to their validity. Postural evaluation methods include visual observation, radiography, photogrammetric, flexicurve, spinal mouse, and inclinometer, among others. Recent advancements suggest 3D analysis methods like 3D radiographs, inertial sensors, and posturometer for assessing lumbar lordosis alteration. Statistical analysis is crucial in in vitro testing of the lumbar spine, with a focus on experimental testing, sample sizes, and statistical power considerations. Additionally, combining digital volume correlation with 3T clinical MRI enables in vivo measurement of spine kinematics and intervertebral disc strains, providing direct information on the mechanical behavior of the spine.What are the most commonly used tools and methods for evaluating low back pain in research studies?

The evaluation of low back pain in research studies commonly involves various tools and methods. These include the i-CONTENT tool for assessing therapeutic quality of exercise interventions in chronic low back pain studies, biomechanical models for calculating cumulative loading on the spine and peak forces, behavioral measures like the pain behavioral scale (PaBS) for assessing pain behaviors in clinical settings, and postural evaluation methods such as visual observation, radiography, and 3D analysis techniques for identifying lumbar lordosis alterations. These tools and methods play crucial roles in understanding, evaluating, and managing low back pain in research settings.How does estrogen affect the production and release of brain-derived neurotrophic factor (BDNF)?

Estrogen plays a crucial role in modulating the production and release of brain-derived neurotrophic factor (BDNF). Studies have shown that estrogen treatment leads to a significant increase in BDNF levels in various scenarios. Estradiol treatment in perimenopausal depression (PD) models upregulates serum BDNF levels, enhancing neuronal survival and excitability through the BDNF/TRPC6 pathway. Additionally, estrogen, particularly through ERβ signaling, influences the expression of BDNF in cortical astrocytes, promoting cell viability and neurotrophic effects. Moreover, sustained estrogen exposure, as seen in estrogen-dependent diseases, can alter the delicate balance of neurotrophins like BDNF, potentially contributing to pathological conditions. Furthermore, estrogen-induced upregulation of BDNF in astrocytes activates the TrkB receptor in triple-negative breast cancer brain metastases, promoting tumor cell invasiveness and metastasis.How does the RAS gene contribute to the development of preeclampsia?

The renin-angiotensin system (RAS) plays a crucial role in the pathogenesis of preeclampsia (PE). Dysregulation of the RAS gene components, such as angiotensin-converting enzyme (ACE) and angiotensin II (Ang II), contributes to the development of PE. Genetic variations in the ACE gene, like the rs4343 polymorphism, have been associated with an increased risk of PE. Additionally, the overactivation of the Ang II/ACE/AT1R axis, along with decreased levels of protective components like ACE 2/Ang 1–7/MasR, can lead to hypertension characteristic of PE. Furthermore, studies suggest that the compensatory alterations in the RAAS during normal pregnancy are disrupted in PE, leading to a disturbance in the delicate equilibrium necessary for maternal and fetal well-being. These findings highlight the intricate involvement of the RAS gene in the pathogenesis of preeclampsia.How does radiation risk vary with age?

Radiation risk varies significantly with age, showing distinct patterns across different populations and cancer types. Studies indicate that children generally exhibit a higher risk of cancer induction from radiation compared to adults, with variations by cancer site and age at exposure. The highest radiation risks are attributed to young individuals, while the lowest risks are seen in advanced ages, with a factor of about 30 difference in detriment across different age groups. Additionally, there is a notable excess of radiation-attributable solid tumors in women compared to men, varying by organ and age, with substantial sex differences in certain cancers exposed between birth and menopause. Furthermore, age-dependent data from animal studies demonstrate increased sensitivity to acute radiation in infants, juveniles, and aging adults, highlighting age-related variability in radiation health effects.Isoflavones: Chemistry, Analysis, Functions and Effects on Health and Cancer

Isoflavones are phytoestrogens found in various plant sources like soy, clover, and legumes. They exhibit estrogenic properties and can act as agonists or antagonists depending on endocrine estrogenic levels. Isoflavones, such as genistein and daidzein, have been linked to positive health effects, including the prevention of hormone-related cancers, cardiovascular disease, osteoporosis, and alleviation of postmenopausal symptoms. These compounds have been studied for their potential benefits in bone health, cancer risk reduction, and menopausal symptom relief. The metabolism and bioavailability of isoflavones play a crucial role in determining their biological effects, with aglycone forms showing stronger activities than conjugated forms. Understanding the pharmacokinetics of isoflavones is essential for maximizing their health benefits.How does menopause affect the structure and appearance of fine and thin hair?

Menopause significantly impacts the structure and appearance of fine and thin hair. Hormonal changes during menopause, particularly the reduction in estrogen levels, lead to various dermatologic alterations, including hair thinning and loss. The decline in estrogen levels affects skin thickness, elasticity, and moisture, contributing to hair atrophy and thinning. Additionally, the imbalance in cytokines due to decreased estrogen levels in menopause can cause dry, wrinkled skin, delayed wound healing, and body hair loss, all of which influence the quality and appearance of scalp hair. Menopausal women may experience changes in hair growth rate, anagen percentage, and hair diameter distributions, particularly in the frontal scalp area, further exacerbating the perception of thinning hair.What is the current state of research on the use of CIPN laser treatment on animal models?

Current research on laser treatment for Chemotherapy-Induced Peripheral Neuropathy (CIPN) in animal models shows promising outcomes. Studies have highlighted the efficacy of low-level laser therapy (LLLT) in modulating biological processes. Additionally, the use of near-infrared (NIR) laser has demonstrated antidepressant and antioxidant effects in animal models of depression. However, the effectiveness of CO2 laser therapy for Genitourinary Syndrome of Menopause (GSM) in a large animal model did not show significant microcirculatory changes. On the other hand, the potential of LLLT in veterinary medicine has been explored, with positive outcomes observed in rodent models using specific laser parameters. Overall, these studies suggest that laser therapy, particularly LLLT, holds promise for treating various conditions in animal models, paving the way for potential clinical applications.What distubs the cycle of hormones?

Disturbances in the cycle of hormones can be influenced by various factors such as adiposity, hormonal administration methods, and interactions between steroid hormones and growth factors. Adiposity, particularly central adiposity, has been linked to alterations in sex hormone patterns across the menstrual cycle, affecting levels of estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone. Additionally, methods of hormonal administration for contraception and menstrual cycle regulation, involving progestins and estrogen-progestin combinations, can impact the hormonal balance. Furthermore, the interplay between steroid hormones and growth factors can affect cell cycle regulation, proliferation, and differentiation, highlighting the importance of understanding these interactions in maintaining hormonal homeostasis. These factors collectively contribute to disturbances in the hormonal cycle, emphasizing the complexity of hormonal regulation in the body.How does menopause and menstrual cycle impact women in the workplace?

Menopause and the menstrual cycle significantly impact women in the workplace. Menopause, a normal occurrence in women, often brings about symptoms like vasomotor symptoms, low self-rated health, sexual difficulties, insomnia, anxiety, and depression, affecting work performance. Menstrual cycles, often neglected in occupational health literature, lead to gendered inequalities at work, requiring women to manage their bodies through additional labor, including dealing with painful symptoms, stigma, and workload balance. Studies show that menopausal symptoms can result in negative work outcomes, leading to economic losses and affecting workplace productivity. Organizational support, understanding, and accommodations for women experiencing menopause and menstrual cycles are crucial to creating inclusive and supportive workplaces that optimize women's health and well-being during this phase of their lives.Do PD-L1 inhibitors slow TNBC xenograft growth in nude mice?

PD-L1 inhibitors have shown efficacy in slowing TNBC xenograft growth in nude mice. Studies using a murine breast cancer model demonstrated that anti-PD-L1 treatment significantly suppressed primary tumor growth and extended survival. Additionally, in a study involving a syngeneic mouse tumor model, Dato-DXd, an ADC targeting TROP2, enhanced antitumor activity when combined with PD-1/PD-L1 inhibitors, suggesting a potential synergy in inhibiting tumor growth. Furthermore, PD-1 blockade in nude mice resulted in decreased tumor growth, indicating the importance of PD-1 signaling in promoting tumor progression. These findings collectively support the notion that PD-L1 inhibitors can effectively slow TNBC xenograft growth in nude mice, highlighting their potential as a therapeutic strategy for TNBC.